EGFR and lung adenocarcinoma: A Dramatic Response to Toripalimab With Chemotherapy and Antiangiogenic Agent Followed by Surgery in a Stage IIIB Lung Adenocarcinoma Patient With an Uncommon <i>EGFR</i> Mutation: A Case Report.